Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Jorge Romero Castañeda and María Eugenia Mendez, Healthcare & Life Science leader and Strategy & Operations Director at Deloitte respectively, share their expertise about the Healthcare & Life Science sector…
Leonardo Torres, general manager Mexico, Central America & Caribbean of Shire, provides insights into the rapidly progressing integration of Baxalta in Mexico, while he also highlights his key priorities to…
Mario Sturion, the recently appointed general manager of Janssen Mexico, assesses the specific challenges and opportunities of the Mexican health system and explains how a customized market access approach has…
Jaime Cervantes, CEO of Vitalmex, provides insights into the company’s ascendent trajectory, with Vitalmex now looking to leverage its leadership position in the public sector to venture in the private market,…
Alfredo Gutierrez, general director of Anfitriones, documents the company’s heightened focus on creating a true experience that goes beyond traditional business events and congresses, its expanded geographical reach to Colombia…
Fabiola Trigueros, founder and CEO at Smart Scale, explains the importance of business intelligence capabilities to undertake proper business decisions and showcases the value proposition of Smart Scale to meet…
Eduardo Gonzalez Pier, former Vice-Minister for Integration and Development of the Health Sector, shares his perspective on current dynamics in Mexico’s public health sector and highlights how collaboration between private…
Alvaro Angel, the recently appointed general manager of the pharmaceutical division of Bayer Mexico, provides insights into the rapidly evolving local pharma market, and documents Bayer Mexico’s ambitious growth strategy;…
Cédric Ertlé, managing director at Laboratoires Expanscience Mexico, explains the strategy that the affiliate has implemented to obtain 20 and 45 percent of growth in dermocosmetics and rheumatology respectively and…
Mayra Galindo Leal, general director of the Mexican Association of the Fight Against Cancer (AMLCC) provides an overview of the main milestones of this association that stands as the most…
José Angel García Hinojosa, counsellor of the board of the Grupo Loeffler Russek, details how Loeffler’s impressive growth has forced the company to increase their manufacturing capacity. While Loeffler grew…
Dr. David Kershenobich Stalnikowitz, General Director of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán on the myriad issues surrounding diabetes in Mexico and how the Mexican healthcare…
See our Cookie Privacy Policy Here
